Differing central amine receptor sensitivity in different migraine subtypes? A neuroendocrine study using buspirone

Pain

Volumn 101, Issue 3, 2003, Pages 283-290

  Cassidy, Eugene M ^a,c   Tomkins, Esther ^a   Sharifi, Neda ^a   Dinan, Timothy ^b   Hardiman, Orla ^a   O'Keane, Veronica ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

5HT1A; Chronic daily headache; Migraine; Prolactin; Serotonin; Stress; Transformed

Indexed keywords

BUSPIRONE; PROLACTIN; PSYCHOTROPIC AGENT; SEROTONIN 1 AGONIST; SEROTONIN RECEPTOR;

ADULT; AGE; ARTICLE; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; EPILEPTIC AURA; FEMALE; GENDER; HUMAN; MENSTRUAL CYCLE; MIGRAINE; NAUSEA; NEUROENDOCRINOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; SIDE EFFECT; VERTIGO;

EID: 0037315996     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(02)00335-4     Document Type: Article

References (70)

1. Anderson I.M., Cowen P.J. Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers. Psychopharmacology. 106:1992;428-432.
2. Bahra A., Matharu M.S., Buchel C., Frackowiak R.S.J., Goadsby P.J. Brainstem activation specific to migraine headache. Lancet. 357:2001;1016-1017.
3. Bakheit A.M., Behan P.O., Dinan T.G., Gray C.E., O'Keane V. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. Br Med J. 304:1992;1566-1567.
4. Barbanti P., Fabbrini G., Vanacore N., Rum A., Lenzi G.L., Meco G., Cerbo R. Dopamine and migraine: does Parkinson's disease modify migraine course? Cephalalgia. 20:(8):2000;720-723.
5. Breslau N., Chilcoat H.P., Andreski P. Further evidence on the link between migraine and neuroticism. Neurology. 47:1996;663-667.
6. Breslau N., Merikangas K., Bowden C.L. Comorbidity of migraine and major affective disorders. Neurology. 44:1994;S17-S22.
7. Breslau N., Schultz L.R., Stewart W.F., Lipton R.B., Lucia V.C., Welch K.M.A. Headache and major depression. Is the association specific to migraine? Neurology. 54:2000;308-313.
8. Breslau N., Schultz L.R., Stewart W.F., Lipton R.B., Welch K.M.A. Headache types and panic disorder. Direction and specificity. Neurology. 56:2001;350-354.
9. Burris T.P., Stringer L.C., Freeman M.E. Pharmacological evidence that a D2 receptor subtype mediates dopaminergic stimulation of PRL secretion from the anterior pituitary gland. Neuroendocrinology. 54:1991;175-183.
10. Bussone G., Frediani F., Lamperti E., LaMantia L., Vescovi A., Peccarisi C., Boiardi A. Piribedil test in migraine: neuroendocrinological aspects. Headache. 26:1986;482-485.
11. Calabresi P., Silvestrini M., Stratta F., Cupini L.M., Argiro G., Atzei G.P., Bernardi G. L-deprenyl test in migraine: neuroendocrinological aspects. Cephalalgia. 13:1993;406-409.
12. Capellan J.I.L., Dacosta C.V., Garcia J.M.G., Servan P.R., Cermeno J.C.A. Tuberoinfundibular dopaminergic tonus in common migraine. Headache. 30:1990;282-284.
13. Castillo J., Martinez F., Suarez C., Naveiro J., Lema M., Noya M. Cerebrospinal fluid tyrosine and 3,4-dihydroxyphenylacetic acid levels in migraine patients. Cephalalgia. 16:(1):1996;56-61.
14. Chaouloff F. Serotonin, stress and corticoids. J Psychopharmacol. 14:2000;139-151.
15. Chugani D.C., Niimura K., Chaturvedi S., Muzik O., Fakhouri M., Lee M-L., Chugani H.T. Increased brain serotonin synthesis in migraine. Neurology. 53:1999;1473-1479.
16. Coccaro E.F., Gabriel S., Mahon T., Macaluso J., Siever L.J. Preliminary evidence of a serotonin (5-HT-1-like) component to the PRL response to buspirone challenge in humans. Arch Gen Psychiatry. 47:1990;594-595.
17. Connor H.E., Feniuk W. Migraine, serotonin and sumatriptan. Vasc Med Rev. 3:1992;95-108.
18. D'Andrea G., Cananzi A.R., Perini F., Hasselmark L. Platelet models and their possible usefulness in the study of migraine pathogenesis. Cephalalgia. 15:1995;265-271.
19. D'Andrea G., Hasselmark L., Alecci M., Cananzi A., Perini F., Welch K.M. Platelet secretion from dense and alpha-granules in vitro in migraine with or without aura. J Neurol Neurosurg Psychiatry. 57:1994;557-561.
20. D'Andrea G., Welch K.M., Nagel-Leiby S., Grunfeld S., Joseph R. Platelet catecholamines in migraine. Cephalalgia. 9:(1):1989;3-5.
21. Dichgans M., Forderreuther S., Deiterich M., Pfaffenrath V., Gasser T. The D2 receptor NcoI allele: absence of allelic association with migraine with aura. Neurology. 51:(3):1998;928.
22. Dinan T.G., Barry S., Yatham L.N., Mobayed M., Brown I. The reproducibility of the PRL response to buspirone: relationship to the menstrual cycle. Int Clin Psychopharmacol. 5:1990;119-123.
23. Dinan T.G., Mahmud N., Rathore O., Thakore J., Scott L.V., Carr E., Naesdal J., O'Morain C.A., Keeling P.W.N. A double-blind placebo-controlled study of buspirone-stimulated PRL release in non-ulcer dyspepsia - are central serotoninergic responses enhanced? Aliment Pharmacol Ther. 15:(10):2001;1613-1618.
24. Glover V., Ahmed F., Hussein N., Jarman J., Peatfield R.C. Central 5-hydroxytryptamine supersensitivity in migraine. Sandler M., Ferrari M., Harnett S. Migraine pharmacology and genetics. 1996;117-126 Chapman and Hall, London.
25. Goadsby P.J. The pharmacology of headache. Prog Neurobiol. 62:2000;509-525.
26. Gordon M.L., Lipton R.B., Brown S.L., Nakraseine C., Russell M., Pollack S.Z., Korn M.L., Merrian A., Solomon S., Van Praag H.M. Headache and cortisol responses to m-chlorophenylpiperazine are highly correlated. Cephalalgia. 13:1993;400-405.
27. Gower A.J., Berendsen H.G., Princen M.M., Broekkamp C.L. The yawning-penile erection syndrome as a model for putative dopamine autoreceptor activity. Eur J Pharmacol. 103:(1-2):1984;81-89.
28. Hamik A., Peroutka S.J. 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry. 25:1989;569-575.
29. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 8:1988;1-96.
30. Heisler L.K., Chu H.M., Brennan T.J., Danao J.A., Bajwa P., Parsons L.H., Tecott L.H. Elevated anxiety and anti-depressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci. 95:1998;15049-15054.
31. Kovacs K., Bors L., Tothfalusi L., Jelencsik I., Bozsik G., Kerenyi L., Komoly S. Cerebrospinal fluid (CSF) investigations in migraine. Cephalalgia. 9:(1):1989;53-57.
32. Lance J.W. Current concepts of migraine pathogenesis. Neurology. 43:1993;S11-S15.
33. Leone M., Attanasio A., Croci D., Ferraris A., D'Amico D., Grazzi L., Nespolo A., Bussone G. 5-HT1A receptor hypersensitivity in migraine is suggested by the m-chlorophenylpiperazine test. NeuroReport. 9:1998;2605-2608.
34. Leone M., Attanasio A., Croci D., Filippini G., D'Amico D., Grazzi L., Nespolo A., Bussone G. The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: a controlled study. Neurology. 55:2000;136-139.
35. Lorentz I.T. A survey of headache in Parkinson's disease. Cephalalgia. 9:(2):1989;83-86.
36. Marcus D. Identification of patients with headache at risk of psychological distress. Headache. 40:2000;373-376.
37. Martignoni E., Facchinetti F., Manzoni G.C., Petraglia F., Nappi G., Genazzani A.R. Abnormal dexamethasone suppression test in daily chronic headache sufferers. Psychiatry Res. 19:1986;51-57.
38. Martignoni E., Facchinetti F., Rossi F., Sances G., Genazzani A.R., Nappi G. Neuroendocrine evidence of deranged noradrenergic activity in chronic migraine. Psychoneuroendocrinology. 14:(5):1989;357-363.
39. Marziniak M, Mössner R, Lesch KP, Sommer C. Altered allelic distribution of a functional polymorphism within the promoter of the serotonin transporter gene in migraine without aura and migraine with aura. Presented at 11th meeting of the European Neurology Society, Paris, France. 2001.
40. Mason P. Central mechanisms of pain modulation. Curr Opin Neurobiol. 9:1999;436-441.
41. Mathew N.T., Reuveni U., Perez F. Transformed or evolutive migraine. Headache. 27:1987;102-106.
42. Mathew N.T., Stubits E., Nigam M.R. Transformation of episodic migraine into daily headache; analysis of factors. Headache. 27:1982;66-68.
43. Mc Allister-Williams R.H., Ferreir I.N., Young A.H. Mood and neuro-psychological function in depression: the role of corticosteroids and serotonin. Psychol Med. 28:1998;573-584.
44. McBride A., Tierney H., DeMeo M., Chen J.S., Mann J.J. Effects of age and gender on CNS serotonergic responsivity in normal adults. Biol Psychiatry. 27:1990;1143-1155.
45. Merikangas K.R., Angst J., Isler H. Migraine and psychopathology. Results of the Zurich cohort study of young adults. Arch Gen Psychiatry. 47:1990;849-853.
46. Murialdo G., Martignoni E., De Maria A., Bonura M.L., Sances G., Bono G., Polleri A. Changes in the dopaminergic control of PRL secretion and in ovarian steroids in migraine. Cephalalgia. 6:1986;43-49.
47. Nagel-Leiby S., Welch K.M., D'Andrea G., Grunfeld S., Brown E. Event-related slow potentials and associated catecholamine function in migraine. Cephalalgia. 10:(6):1990;317-329.
48. Nappi G., Savioldi F., Bono G., Martignoni E. Reserpine - headache and PRL release in migraine. Headache. 19:1979;273-277.
49. Nattero G., Corno M., Savi L., Isaia G.C., Priolo C., Mussetta M. PRL and migraine: effect of L-dopa on plasma PRL levels in migraineurs and normals. Headache. 26:1986;9-12.
50. O'Keane V., O'Hanlon M., Webb M., Dinan T.G. D-fenfluramine/PRL response throughout the menstrual cycle: evidence for an oestrogen-induced alteration. Clin Endocrinol. 34:1991;289-292.
51. Paalzow G.H. L-Dopa induces opposing effects on pain in intact rats: (-)-sulpiride, SCH 23390 or alpha-methyl-alpha-methyl-DL-p-tyrosineDL-p-tyrosine methylester hydrochloride reveals profound hyperalgesia in large antinociceptive doses. J Pharmacol Exp Ther. 263:(2):1992;470-479.
52. Peroutka S.J. Dopamine and migraine. Neurology. 49:(3):1997;650-656.
53. Pinessi L., Rainero I., Savi L., Valfre W., Limone P., Calvelli P., Del Rizzo P., Gianotti L., Taliano M., Ghigo E., Arvat E. Effect of subcutaneous sumatriptan on plasma growth hormone concentrations in migraine patients. Cephalalgia. 20:2000;223-227.
54. Pineyro G., Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev. 51:1999;533-591.
55. Polleri A., Nappi G., Masturzo P., Martignoni E., Murialdo G., Bono G., Testa E., Savoldi F. Neuroendocrine approach to headache. McDonald Critchley, Friedman A.P., Gorini S., Sicuteri F. Advances in neurology. 1982;173-182 Raven Press, New York, NY.
56. Pradalier A., Launay J.M., Dry J., Dreux C., Artigou C. Common migraine. Changes in conjugated and unconjugated catecholamines. Presse Med. 14:(10):1985;583-585.
57. Raskin N.H., Hosobuchi Y., Lamb S. Headache may arise from perturbation of brain. Headache. 27:1987;416-420.
58. Ribeiro C.A., Cotrim M.D., Morgadinho M.T., Ramos M.I., Santos E.S., de Macedo T.D. Migraine, serum serotonin and platelet 5-HT2 receptors. Cephalalgia. 10:1990;213-219.
59. Rotondo A., Nielsen D.A., Nakhai B., Hulihan-Giblin B., Bolos A., Goldman D. Agonist-promoted down-regulation and functional desensitisation in two naturally occurring variants of the human serotonin1A receptor. Neuropsychopharmacology. 17:(1):1997;18-26.
60. Sarchielli P., Alberti A., Russo S., Codini M., Panico R., Floridi A., Gallai V. Nitric oxide pathway, Ca2+, and serotonin content in platelets from patients suffering from chronic daily headache. Cephalalgia. 19:1999;810-816.
61. Silberstien S.D., Lipton R.B., Sliwinski M. Classification of daily and near-daily headaches: a field study of revised HIS criteria. Neurology. 47:1996;871-875.
62. Sramek J.J., Hong W.W., Hamid S., Nape B., Cutler N.R. Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety. Depress Anxiety. 9:1999;131-134.
63. Srikiatkhachorn A., Maneesri S., Govitrapong P., Kasantikul V. Derangement of serotonin system in migrainous patients with analgesic abuse headache: clues from platelets. Headache. 38:1998;43-49.
64. Srikiatkhachorn A., Tarasub N., Govitrapong P. Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. Headache. 40:(5):2000;343-350.
65. Stewart W.F., Lipton R., Swayer J. An international study to assess the reliability of the migraine disability assessment (MIDAS) score. Neurology. 52:1999;988-994.
66. Van De Kar L.D., Bethea C.L. Pharmacological evidence that serotonergic stimulation of PRL release is mediated via the dorsal raphe nucleus. Neuroendocrinology. 35:1982;225-230.
67. Veloso F., Kumar K., Toth C. Headache secondary to deep brain implantation. Headache. 38:1998;507-515.
68. Weiller C., May A., Limmroth V., Juptner M., Kaube H., Schayck R.V., Diener H.C. Brainstem activation in spontaneous human migraine attacks. Nat Med. 1:1995;658-660.
69. Yilmaz M., Erdal M.E., Herken H., Cataloluk O., Barlas O., Bayazit Y.A. Significance of serotonin transporter gene polymorphism in migraine. J Neurol Sci. 186:(1-2):2001;27-30.
70. Zhuang X., Gross C., Santarelli L., Compan V., Trillat A.C., Hen R. Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors. Neuropsychopharmacology. 21:(Suppl. 2):1999;52S-60S.